Amgen fell sharply after a Novartis drug trial failure changed the competitive outlook for its cardiovascular pipeline. OpenAI released a new model called Astra, and AI infrastructure stocks surged in response. Today’s edition covers both stories, Intel’s surprise 9% day, and every name that moved.
Gold Before Change (Sponsored)
In 1971, one Sunday-night announcement changed the dollar almost overnight.
Today, investors are again asking what inflation, policy shifts, and rising central-bank gold demand could mean for retirement savings.
This free guide explains why gold is back in focus, how physical gold can fit into certain retirement strategies, and what some investors are doing to prepare before the next major monetary shift.
Get the Free Gold Guide Before the Next Move.
Elite Trade Club Insider
A CEO Sold $43.4 Million While A Director Put Nearly $10 Million Into A 9% Preferred
You’re looking at one of the world’s biggest AI winners and a telecom operator trying to improve cash flow across Latin America and the Caribbean. Elite Trade Club Insider readers are seeing what the raw filings miss: one CEO sold $43.4 million, but the transaction was tied to freshly vested compensation and a preset plan, while a director-associated entity voluntarily committed nearly $10 million to a high-yielding preferred security.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Markets
Novartis said Friday that pelacarsen, its experimental heart disease drug, failed to reduce cardiovascular risk in a late-stage trial — and on Tuesday, Amgen fell 10% in its worst single session since October 2000, because Amgen and Eli Lilly are developing rival treatments that were assumed to benefit from the same biology; Novartis tumbled 10% in Europe, and Eli Lilly dipped too, making health care the S&P 500’s worst-performing sector.
OpenAI released Astra, its latest model, and AI infrastructure stocks moved the opposite way from the rest of the market: CoreWeave jumped 15%, Lumentum 12%, and Coherent 9%, while quantum computing names also caught a bid. Intel rose 9% after an analyst upgrade and reports that the company is planning to raise CPU prices.
GE Aerospace announced it will acquire Consolidated Precision Products — the maker of the blades and vanes that go inside jet engines — for $11.75 billion, bringing in-house a supplier it has relied on for 15 years. Boston Scientific lowered its full-year sales and earnings targets after last month’s cyberattack left it unable to process and ship cardiac device orders; the stock is now down 52% from a year ago.
DJIA [-1.18%]
S&P 500 [-0.58%]
Nasdaq [-0.32%]
Russell 2000 [-0.52%]
Market-Moving News
AI & Cloud
Goldman Sachs Opens Bellevue Engineering Office for AI Expansion
Goldman Sachs has opened a dedicated engineering office in Bellevue, Washington, for more than 125 employees focused on artificial intelligence and cloud transformation, expanding its technology operations in a region known for engineering talent.
The bank already employs more than 12,000 engineers, roughly one-quarter of its global workforce, and the new location strengthens its access to specialists who develop the systems supporting its businesses as management makes technology hiring central to its growth plans.
Qualcomm Partners With Amazon on Custom AI Chips
Qualcomm has partnered with Amazon to develop custom chips for AI data centers, extending its expansion beyond smartphones through a collaboration covering processors designed to run trained AI models and high-speed optical connections for moving data.
The companies also plan to develop connectivity supporting speeds of up to 1.6 terabits per second, and Qualcomm will expand its use of Amazon Web Services for chip-design workloads to shorten development cycles.
Finance and Banking
Robinhood Adds Trading Partner as Prediction Markets Expand
Robinhood Markets will route selected football contracts through OG.com, adding another exchange to its prediction-market platform while taking equity stakes in both OG.com and Crypto.com under a partnership that begins rolling out to eligible customers.
The agreement expands Robinhood’s trading infrastructure after event contracts generated a record $156 million in second-quarter revenue, with OG.com providing a derivatives exchange and clearinghouse regulated by the Commodity Futures Trading Commission alongside Robinhood’s existing trading partners.
JPMorgan Strengthens Canadian Equities Business With Senior Hire
JPMorgan Chase has hired Chris Finora from Canada’s pension giant to lead its Canadian cash equities trading business, bringing the Canada Pension Plan Investment Board’s equities trading head to Toronto as the bank expands its local platform.
Finora joins this month following roughly two years at the pension manager and 27 years at TD Securities, extending a hiring push that added 18 executives and managing directors in Canada over the past year and increased director headcount by 20%.
Aerospace and Defense
Boeing’s Dreamliner Deliveries Slow, but Annual Target Holds
Boeing delivered 51 commercial jets in August, down from 57 a year earlier, as Dreamliner handovers fell to four from nine, although the company said the decline did not reflect production, supply chain or certification problems.
The planemaker maintained its target of delivering 90 to 100 Dreamliners this year, while total aircraft deliveries reached 418 through August, its strongest first eight months since 2018 despite the latest monthly slowdown.
GE Aerospace Moves to Secure Engine Parts With $11.75 Billion Deal
GE Aerospace agreed to buy Consolidated Precision Products for $11.75 billion, bringing a major castings supplier inside the company as engine manufacturers work to expand production and meet demand for commercial aircraft, military equipment and replacement parts.
The acquisition will be funded with existing cash and new debt, with closing expected in the second half of 2027, and GE expects it to increase adjusted earnings per share and free cash flow in the first year.
Growth Watch (Sponsored)
After analyzing thousands of companies, our analysts pinpointed the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.
This newly released report explains why these five could be positioned for major moves in the year ahead.
While results aren’t guaranteed, previous reports uncovered gains as high as +175%, +498%, and +673%.
Access the free report before midnight.
See the 5 Stocks Set to Double.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Health and Pharma
Intellia’s Gene-Editing Treatment Gets FDA Priority Review
Intellia Therapeutics secured FDA priority review for lonvo-z, its experimental treatment for hereditary angioedema, and the agency set March 10, 2027, as its target date to decide on the application.
If approved, the therapy would become the first CRISPR treatment to edit genes inside the body and the only one-time treatment for the disease, according to the company, which reported positive Phase 3 results.
Bristol Myers’ Cell Therapy Clears a Key Blood-Cancer Trial
Bristol Myers Squibb said its experimental cell therapy arlo-cel met its main Phase 2 goal in patients with advanced multiple myeloma who had already received four major classes of treatment, including therapies targeting a different cancer-cell protein.
The study also met its complete-response goal, but detailed results remain unpublished and are scheduled for an upcoming medical meeting, so the size of the benefit remains undisclosed.
Retail and Banking
Eagle and John Marshall Agree to a $253 Million Bank Merger
Eagle Financial Services and John Marshall Bancorp have agreed to combine in a stock merger valued at approximately $253 million, bringing together their Virginia banking businesses under the John Marshall name while preserving both banks’ existing customer-facing brands.
Eagle shareholders will receive two John Marshall shares for each share they own, with the combined company headquartered in Reston and the transaction expected to close early in 2027, subject to regulatory and shareholder approvals.
Amazon Faces Lawsuit Over Treatment of Pregnant Warehouse Workers
Amazon faces a proposed class action over pregnancy discrimination brought by four former warehouse employees, who allege the retailer denied basic workplace accommodations, including seating, bathroom breaks and time off for prenatal appointments.
The complaint, filed in Brooklyn federal court, seeks lost pay, benefits, and punitive damages and challenges alleged practices involving medical documentation and dismissals related to time off; Amazon has not yet responded to a request for comment.
Top Winners and Losers
CEA Industries [BNC] $5.25 (+50.43%)
CEA Industries pivoted earlier this year from controlled environment agriculture to a BNB Chain treasury strategy, and today the stock ran 50% after BNB Chain’s launchpad Four.meme launched BNC4 — the first tokenized Nasdaq stock product tied one-to-one to BNC shares.
Binance founder CZ posted on X that “IPOs will move on chain,” and crypto traders seeking on-chain exposure to the stock bought the underlying shares to access it. The product attracted over $2 million in mint requests within hours of launch.
System1 [SST] $5.00 (+30.55%)
System1 operates a programmatic advertising and customer acquisition platform, generating revenue from targeted digital marketing across owned and operated web properties.
The company reported Q2 results that beat expectations on revenue growth and improved gross margins, showing that its consent-based advertising approach is gaining traction even as the broader ad market navigates uncertainty.
Swvl Holdings [SWVL] $6.42 (+30.22%)
Swvl runs a mass transit platform connecting riders and operators across the Middle East, Africa, and Southeast Asia. With the region’s logistics and transportation demand elevated by ongoing Hormuz shipping disruptions and urban mobility pressure, Swvl’s regional positioning is drawing renewed interest.
The company is P/E positive and generating revenue from a growing base of city transport contracts.
Focus Universal [FCUV] $5.91 (-65.24%)
Focus Universal appeared in the top winners list for four consecutive sessions in late August and early September, running from $11 to $19 on thin-float momentum.
Today the same mechanics ran in reverse: the momentum broke, buyers stepped away, and the stock fell 65% in a single session. The IoT connectivity platform business is unchanged. The price was not built on fundamentals, so it had no fundamentals to hold it.
bioAffinity Technologies [BIAF] $8.93 (-41.52%)
bioAffinity’s CancerSEEK blood-based lung cancer detection platform drove five sessions of 19-48% daily gains starting September 1, taking the stock from $4.50 to $15.27.
The reversal is now underway: -41% today brings it back to $8.93, still 98% above where the run started. The clinical technology is real; the trading was a momentum squeeze, and those unwind the same way they build.
Lexaria Bioscience [LEXX] $9.37 (-33.78%)
Lexaria owns patents on DehydraTECH, its drug delivery technology that improves bioavailability of active ingredients including cannabinoids and nicotine.
The stock ran in multiple sessions through August and early September, and today is giving back a significant portion of those gains as the momentum cycle rotates. The IP portfolio is intact; the premium built by momentum trading is compressing.
A stock you've been watching for 2 years just dropped to your price target. It's finally in your buy zone. What actually happens?
- I buy it. I did the work two years ago, the thesis is the same, this is exactly what I was waiting for.
- I hesitate. Something about it dropping makes me want to wait and see if it goes lower.
- I immediately re-underwrite the whole thing from scratch. Two years is a long time and I'm not sure the thesis still holds.
- I buy half now and wait to add. I'm never confident enough to go full size all at once.
A New Warning (Sponsored)
Elon Musk is now paying you 15X more than your bank… Thanks to a project he's been working on for the last 27 years. All you have to do is sign up for his new bank. For years, America's biggest banks have been telling you they have no choice but to pay you interest rates as low as 0.4% (that's the national average).
Now, suddenly… Elon is exposing many of these bankers for the sharks they really are. He's not offering double… or triple… or even five times the interest… But 15 times the national average — at 6% per year.
This is just one of the radical ways Elon's new bank is disrupting the financial sector…
Luke Lango is revealing how it could impact your money (and how you should prepare) here.
*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
Everything Else
💡 Most investors will only notice these 7 stocks after the move has already happened and right now they are still grinding outside the spotlight with the kind of fundamentals that tend to matter later.
🔎 Google warned that its revamped European search results could deliver lower quality as the company changes its service to avoid fresh EU regulatory penalties.
📉 The S&P 500 and Dow slipped at the open as Fed rate-hike expectations remained elevated, with higher oil prices adding another layer of pressure on Wall Street.
📱 Apple’s John Ternus faces a major AI test as the foldable iPhone takes center stage, putting the hardware chief in the spotlight as Apple prepares its next big product push.
🍁 Canada’s retaliatory tariffs on U.S. goods officially took effect as trade negotiations with Washington remain stalled.
⚛️ Holtec Nuclear is targeting a $10.2 billion valuation in its U.S. IPO, kicking off the fall listing season with a major test of Wall Street’s appetite for nuclear energy.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE ELON INDEX
Our conviction bet on the Musk universe: Tesla, and the companies orbiting his ventures, energy, AI, infrastructure. High-beta by design, for investors who want direct exposure to the trade rather than watching it from the sidelines.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!
Thanks for reading. I'll see you at the next open!
Best Regards,
— Adam G.
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
